Tumor resistance to ADT is cumulative: with the change of lineage, some tumor cells will eventually lose AR expression and develop into small cell carcinoma; this type of tumor is called neuroendocrine prostate cancer (NEPC), and this type of cancer cells express neuroendocrine markers, mostly induced by treatment, and a small part is primary, and does not respond to ARSI et al. [112]. This evidence concerns the gene AR and cancer.